IBBR Publications

Found 7 results
Filters: Author is Hsu, Janet  [Clear All Filters]
2017
Kim J, Sinha S, Solomon M, Perez-Herrero E, Hsu J, Tsinas Z, Muro S. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance. Biomaterials. 2017 ;147:14-25.
2014
Papademetriou I, Tsinas Z, Hsu J, Muro S. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes. J Control Release. 2014 ;188C:87-98.
Hsu J, Bhowmick T, Burks SR, P Y Kao J, Muro S. Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers. J Biomed Nanotechnol. 2014 ;10(2):345-54.
Hsu J, Rappaport J, Muro S. Specific Binding, Uptake, and Transport of ICAM-1-Targeted Nanocarriers Across Endothelial and Subendothelial Cell Components of the Blood-Brain Barrier. Pharm Res. 2014 .
Hsu J, Hoenicka J, Muro S. Targeting, Endocytosis, and Lysosomal Delivery of Active Enzymes to Model Human Neurons by ICAM-1-Targeted Nanocarriers. Pharm Res. 2014 .
2012
Hsu J, Northrup L, Bhowmick T, Muro S. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine. 2012 ;8(5):731-9.
2011
Hsu J, Serrano D, Bhowmick T, Kumar K, Shen Y, Kuo YChia, Garnacho C, Muro S. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release. 2011 ;149(3):323-31.